Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H5UL | ISIN: LU0569974404 | Ticker-Symbol: 7AA
Tradegate
15.01.25
10:49 Uhr
25,620 Euro
+0,280
+1,10 %
1-Jahres-Chart
APERAM SA Chart 1 Jahr
5-Tage-Chart
APERAM SA 5-Tage-Chart
RealtimeGeldBriefZeit
25,66025,70012:00
25,66025,70012:00
Dow Jones News
638 Leser
Artikel bewerten:
(2)

Aperam S.A.: Aperam update on Q2 2024 market & financial trends

Finanznachrichten News

DJ Aperam update on Q2 2024 market & financial trends

Aperam S.A. / Key word(s): Miscellaneous 
Aperam update on Q2 2024 market & financial trends 
01-Jul-2024 / 06:59 CET/CEST 
=---------------------------------------------------------------------------------------------------------------------- 
Aperam update on Q2 2024 market & financial trends 
 
Luxembourg, July 1, 2024 (07:00 CET) - In preparation of the quarterly results release scheduled for 1 August 2024, we 
would like to remind market participants of the standing guidance, earnings drivers and events that should be 
considered. 
The Q2 outlook, as specified in the Q1 presentation, the management podcast and during the conference call was: 
   -- Q2 group adj. EBITDA higher than Q1-24 (EUR55m) but below Bloomberg consensus at the time of the earnings 
  release on 3 May 2024. This was based on slightly higher volumes, the segment trends stated in the table below and 
  stable commodity prices resulting in a neutral inventory valuation. 
   -- This compares to the Aperam compiled Q2 adj. EBITDA consensus at EUR73m currently. The consensus is 
  updated & published at https://www.aperam.com/investors/news-contacts/results/ 
 
Recycling &    Normalised annual EBITDA of EUR80-85m. We projected Q2 to be a normal quarter for the segment. 
Renewables: 
Stainless &    For Q2 we projected the segment to benefit from a neutral inventory valuation and a seasonal volume 
Electrical Europe improvement in Europe. This will be partly offset by a price / cost squeeze in Europe. 
Stainless &    The delayed ramp-up of the hot rolling mill was followed by operational instability. This will fully 
Electrical Brazil impact Q2 with EUR10m. 
Alloys &     For Q2 we expected a somewhat lower EBITDA in line with Q4-23 after completion of a one off project. 
Specialties: 
Services &    Assuming no further distortion from raw material prices, we expected a comparable EBITDA in Q2 and 
Solutions:    the year should demonstrate a clear step towards the 2025 improvement target. 
Others &     Q1 was consistent with the normal high single digit negative EBITDA that should be expected. For Q2, 
Eliminations   it could be a negative low double digit number. 
         NWC: EUR120m release till YE-24 with some release in Q2. 
Cash Flow & Net  Capex EUR150m for 2024, Q2 capex lower than Q1 (EUR81m) and within the EUR150m capex guidance for 
Fin. Debt:    2024. 
         Q2 net debt: Lower due to the release of net working capital. 

Please note that forward guidance for adj. EBITDA, cash flow and net debt is always provided on a stable commodity price assumption.

Commodity prices & FX:

MAR 24 APR 24 MAY 24 JUN 24 
Nickel LME      USD/t 17,409 18,204 19,605 17,602 
Ferrochrome      USD/t 3,483 3,218 3,174 3,163 
Stainless Scrap    USD/t 1,478 1,463 1,552 1,538 
Stainless CR 2mm 304 USD/t 2,889 2,944 3,040 3,191 
USD/EUR        x   1.09  1.07  1.08  1.08 
USD/BRL        x   4.98  5.13  5.14  5.38 

Source: Bloomberg, Fastmarkets

Other items: 
Seasonality:     In a normal market, Q2 is the seasonal peak in Europe while Q3 marks the peak quarter in Brazil. 
Leadership Journey  On track to realise the target gains of EUR75m in 2024. 
Phase 5: 
Commodity prices &  At face value, the commodity price development would indicate a positive high single digit / very 
inventory valuation: low double digit inventory valuation. It should remain consistent with the EBITDA ceiling guided 
           for Q2. 
Brazil hot rolling  The mill is operating normally and no further impact is expected post Q2. 
mill: 
Distributor      Marked a new post GFC all time low. 
Inventory: 
           A positive price / volume correlation can be observed more recently. However, it remains open if 
Current trading:   this is the start of a sustained recovery or short lived pre-buying ahead of the summer holiday 
           season 
Restructuring:    Negotiations with our workforce are ongoing. 

Forward Looking Statements

This document may contain forward-looking information and statements about Aperam SA and its subsidiaries. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements may be identified by the words "believe", "expect", "anticipate", "target" or similar expressions. Although Aperam's management believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Aperam's securities are cautioned that forward-looking information and statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Aperam, that could cause actual results and developments to differ materially and adversely from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in Aperam's filings with the Luxembourg Stock Market Authority for the Financial Markets (Commission de Surveillance du Secteur Financier). The information is valid only at the time of release and Aperam does not assume any obligation to update or revise its forward-looking statements on the basis of new information, future events, subject to applicable regulation.

Contact

Company Secretary / Delphine Féraud Valendru: aperam.corporate@aperam.com

Investor Relations / Thorsten Zimmermann: +352 27 36 27 304; thorsten.zimmermann@aperam.com

-----------------------------------------------------------------------------------------------------------------------

Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

1936231 01-Jul-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1936231&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

July 01, 2024 00:59 ET (04:59 GMT)

© 2024 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.